Global Neuroendocrine Carcinoma Market Trends and Future Outlook to 2029
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Predicted Market Size Of The Neuroendocrine Carcinoma Industry By 2029?
The market size for neuroendocrine carcinoma has seen significant growth in recent years. There is an expected increase from $1.63 billion in 2024 to $1.75 billion in 2025, representing a compound annual growth rate (CAGR) of 7.4%. Factors contributing to this historic growth can be linked to the expanding imaging sector, a heightened occurrence of neuroendocrine tumors, escalating investment levels, augmented government initiatives, and the rising need for neuroendocrine tumor treatments.
The market size of neuroendocrine carcinoma is projected to experience substantial growth in the coming years, expanding to $2.31 billion by 2029 at a compound annual growth rate (CAGR) of 7.2%. This predicted growth within the prognosis period is primarily due to the rising prevalence of cancer, acceleration in product approvals, the upsurge in the utilization of advanced diagnostic imaging techniques, the development of targeted therapies, and the increasing number of available diagnosis and treatment options. Notable trends during the projection timeframe incorporate advancements in diagnostic technology, improved imaging technology, focused treatment strategies, progress in managing neuroendocrine tumors, and the evolution of targeted therapies and immunotherapies.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21229&type=smp
Which Factors Are Steering Growth In The Neuroendocrine Carcinoma Market?
The neuroendocrine carcinoma market’s progression is anticipated to be bolstered by the rise of targeted therapies. These treatments are specifically devised to accurately target and interrupt the molecular processes or genetic changes responsible for a disease, primarily cancer. The surge in demand for targeted therapies is attributed to their accuracy in addressing particular genetic mutations, the evolution of personalized medicine, and improved patient results with fewer side effects. Neuroendocrine carcinoma paves the way for the creation of targeted therapies that uniquely attend to the biochemical and genetic profiles of the tumor, thereby amplifying the precision and efficiency of treatment. For example, the American Society of Gene & Cell Therapy (ASGCT), a professional membership organization in the US, and Citeline, a US-based drugs and devices provider, reported in July 2023 that by the end of Q1 2023, Phase II had 247 gene therapies but this figure increased by 5% to hit 260 by the end of Q2. Thus, the expansion of targeted therapies is fuelling the growth of the neuroendocrine carcinoma market.
Which Segment Accounts For The Largest Share In The Neuroendocrine Carcinoma Market?
The neuroendocrine carcinomamarket covered in this report is segmented –
1) By Type: Gastroenteropancreatic Neuroendocrine Tumors; Carcinoid Tumors; Pheochromocytoma; Medullary Thyroid Carcinoma
2) By Diagnostic Tools: Imaging; Biopsy; Serology
3) By Treatment: Chemotherapy; Radiotherapy; Surgery; Other Treatments
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End-User: Hospitals; Clinics; Oncology Centers; Ambulatory Surgery Centers
Subsegments:
1) By Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Pancreatic Neuroendocrine Tumors (pNETs); Small Intestinal Neuroendocrine Tumors; Gastric Neuroendocrine Tumors; Colorectal Neuroendocrine Tumors
2) By Carcinoid Tumors: Pulmonary Carcinoid Tumors; Gastrointestinal Carcinoid Tumors
3) By Pheochromocytoma: Adrenal Pheochromocytoma; Extra-Adrenal Paraganglioma
4) By Medullary Thyroid Carcinoma: Sporadic Medullary Thyroid Carcinoma; Hereditary Medullary Thyroid Carcinoma (MEN2-Associated)
Which Disruptive Trends Are Driving Change Across The Neuroendocrine Carcinoma Market?
Leading companies in the neuroendocrine carcinoma market are developing advanced therapies such as targeted radiopharmaceutical therapy to improve treatment precision and patient outcomes. This therapy uses radioactive molecules that selectively target cancer cells to deliver radiation while sparing healthy tissues. For instance, in September 2024, Abdera Therapeutics Inc., a Canadian biotech firm, received FDA orphan drug designation for ABD-147 for treating neuroendocrine carcinoma. ABD-147 targets tumors expressing the DLL3 protein, commonly elevated in aggressive cancers like small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). The orphan drug status offers development incentives such as tax credits and potential market exclusivity, positioning ABD-147 as a promising treatment option in this specialized field.
Who Are The Dominant Players In The Neuroendocrine Carcinoma Market Today?
Major companies operating in the neuroendocrine carcinoma market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Amgen Inc., Boehringer Ingelheim GmbH, Exelixis Inc., Lantheus Holdings Inc., HUTCHMED Limited, Dana-Farber Cancer Institute Inc., Abdera Therapeutics Inc., Orano Med S.A, Eckert & Ziegler Radiopharma GmbH, Callisto Pharmaceuticals Inc., RadioMedix Inc., Clarity Pharmaceuticals Limited, Delcath Systems Inc., Provectus Biopharmaceuticals Inc.
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/neuroendocrine-carcinoma-global-market-report
What Regional Factors Are Accelerating Growth In The Neuroendocrine Carcinoma Market?
North America was the largest region in the neuroendocrine carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroendocrine carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=21229&type=smp
Browse Through More Reports Similar to the Global Neuroendocrine Carcinoma Market 2025, By The Business Research Company
Neuroendocrine Tumor Treatment Global Market Report 2025
Hepatocellular Carcinoma Drugs Global Market Report 2025
Unresectable Hepatocellular Carcinoma Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
